Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition.

Bray K, Mathew R, Lau A, Kamphorst JJ, Fan J, Chen J, Chen HY, Ghavami A, Stein M, DiPaola RS, Zhang D, Rabinowitz JD, White E.

PLoS One. 2012;7(7):e41831. doi: 10.1371/journal.pone.0041831. Epub 2012 Jul 26.

2.

Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.

Li H, Jin X, Zhang Z, Xing Y, Kong X.

Cell Biochem Funct. 2013 Jul;31(5):427-33. doi: 10.1002/cbf.2917. Epub 2012 Oct 22.

PMID:
23086777
3.

FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells.

Zhang L, Wang H, Ding K, Xu J.

Toxicol Lett. 2015 Jul 2;236(1):43-59. doi: 10.1016/j.toxlet.2015.04.015. Epub 2015 May 1.

PMID:
25939952
4.

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12.

6.

Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.

Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.

Carcinogenesis. 2013 Jun;34(6):1331-42. doi: 10.1093/carcin/bgt060. Epub 2013 Feb 7.

PMID:
23393227
7.

Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.

Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y, Zhao WL.

Cell Death Dis. 2012 Mar 1;3:e275. doi: 10.1038/cddis.2012.13.

8.

Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.

Vucicevic L, Misirkic M, Janjetovic K, Vilimanovich U, Sudar E, Isenovic E, Prica M, Harhaji-Trajkovic L, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V.

Autophagy. 2011 Jan;7(1):40-50. Epub 2011 Jan 1.

PMID:
20980833
9.

Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.

Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM, Boucher MJ.

J Biol Chem. 2015 Feb 27;290(9):5592-605. doi: 10.1074/jbc.M114.616714. Epub 2015 Jan 5.

10.

Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.

Chen SM, Liu JL, Wang X, Liang C, Ding J, Meng LH.

Biochem Pharmacol. 2012 May 1;83(9):1183-94. doi: 10.1016/j.bcp.2012.01.019. Epub 2012 Jan 26.

PMID:
22305748
11.

Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.

Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, Pollock RE, Lev D.

Mol Cancer Ther. 2012 Aug;11(8):1758-69. doi: 10.1158/1535-7163.MCT-12-0015. Epub 2012 Jul 30.

12.

The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.

Inglis DJ, Lavranos TC, Beaumont DM, Leske AF, Brown CK, Hall AJ, Kremmidiotis G.

Cancer Biol Ther. 2014;15(11):1552-60. doi: 10.4161/15384047.2014.956605.

13.

Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.

Zheng B, Mao JH, Qian L, Zhu H, Gu DH, Pan XD, Yi F, Ji DM.

Cancer Lett. 2015 Feb 28;357(2):468-75. doi: 10.1016/j.canlet.2014.11.012. Epub 2014 Nov 12.

PMID:
25444920
14.

Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.

Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, Khuri FR, Sun SY.

Cancer Res. 2009 Dec 1;69(23):8967-76. doi: 10.1158/0008-5472.CAN-09-2190. Epub 2009 Nov 17.

15.

Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.

Wu M, Si S, Li Y, Schoen S, Xiao GQ, Li X, Teh BT, Wu G, Chen J.

Oncotarget. 2015 Oct 20;6(32):32761-73. doi: 10.18632/oncotarget.5018.

16.

Akt and mTOR mediate programmed necrosis in neurons.

Liu Q, Qiu J, Liang M, Golinski J, van Leyen K, Jung JE, You Z, Lo EH, Degterev A, Whalen MJ.

Cell Death Dis. 2014 Feb 27;5:e1084. doi: 10.1038/cddis.2014.69.

17.

Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.

Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.

Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12.

18.

Akt and autophagy cooperate to promote survival of drug-resistant glioma.

Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA.

Sci Signal. 2010 Nov 9;3(147):ra81. doi: 10.1126/scisignal.2001017.

19.

mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.

Bailey ST, Zhou B, Damrauer JS, Krishnan B, Wilson HL, Smith AM, Li M, Yeh JJ, Kim WY.

PLoS One. 2014 Sep 2;9(9):e104413. doi: 10.1371/journal.pone.0104413. eCollection 2014.

20.

Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.

Lee HO, Mustafa A, Hudes GR, Kruger WD.

PLoS One. 2015 Jul 2;10(7):e0131464. doi: 10.1371/journal.pone.0131464. eCollection 2015.

Supplemental Content

Support Center